Press Releases

First OX40 agonist to demonstrate clinical benefit in a randomized studyINBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab aloneResults are most pronounced in HPV+ patients, with cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab aloneInhibrx will expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a potential pathway to accelerated approvalPositive results support large expansion opportunities into highly immunogenic tumors and combination with cancer vaccinesSAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Inhibrx Biosc

RESTON, Va., Sept. 8, 2026 /PRNewswire/ -- V2X, Inc. (NYSE:VVX) today announced it has been awarded a $19 million indefinite-delivery/indefinite-quantity contract by the U.S. Marine Corps to deliver Tempest counter-Unmanned Aerial System (C-UAS) vehicles, expanding access to a highly mobile capability designed to protect maneuver forces against rapidly evolving unmanned threats. Under the contract, V2X will provide Tempest vehicles along with maintenance support, software management, spares, ancillary components, training, and other associated engineering services. Designed for speed, mobility, and adaptability, Tempest provid

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Safehold Inc. (NYSE:SAFE), the creator and leader of the modern ground lease industry, has closed on a ground lease for the development of an Affordable Housing community in San Antonio, Texas. The Low-Income Housing Tax Credit development will provide 336 total units upon delivery in 2028. The project will be developed by The NRP Group, one of the most active developers of Affordable Housing in the United States and a repeat Safehold customer. "This is a high-quality development in a growing San Antonio market, and we're pleased to partner again with The NRP Group while continuing to exp

Milestone helps bring Iowa's only nuclear energy center back online, strengthen grid reliability and meet growing electricity demand JUNO BEACH, Fla., Sept. 8, 2026 /PRNewswire/ -- NextEra Energy, Inc. (NYSE:NEE) today announced that it and the U.S. Department of Energy (DOE), through its Office of Energy Dominance Financing (EDF), have reached a combined conditional commitment and financial close on a loan of up to $1.9 billion to support the restart of the company's Duane Arnold Energy Center in Iowa. This milestone moves the company closer to restoring Iowa's only nuclear plant and adding reliable, around-the-clock energy to the regional grid.

Acclaimed roller coaster will debut at a Six Flags park during the 2028-2029 seasons, launching speculation among coaster fans worldwideARLINGTON, Texas, Sept. 8, 2026 /PRNewswire/ -- Six Flags Entertainment Corporation (NYSE:FUN), North America's largest regional amusement-resort operator, has acquired ArieForce One, the celebrated steel roller coaster that captured the imagination of thrill-seekers around the world and quickly earned recognition as one of the most acclaimed coaster experiences of the modern era. Six Flags will introduce the attraction at one of its parks during the 2028-2029 operating seasons. While the coaster's future home remains under wraps,

Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Seabridge Gold Inc. (TSX:SEA) (NYSE:SA) ("Seabridge" or the "Company") announces substantial completion and successful energization of the Treaty Creek Terminal ("TCT") on August 27, 2026, a significant milestone in the development of infrastructure supporting the Company's KSM Project in northwestern British Columbia.The terminal, located on highway 37 approximately 2 kilometers north of the entrance to the KSM Project, represents a key component of the electrical infrastructure required to support future construction and operations at KSM. The facility is expected to be ready for service by November 2026.Rudi Fronk, Chair and CEO of

IonQ (NYSE:IONQ), the world’s leading full-stack quantum platform and foundry, today announced that, for the full year 2026, it expects revenue to be between $450 million and $460 million. This outlook includes the contributions of SkyWater Technology beginning on July 31, 2026, the date it was acquired by IonQ, through to Dec. 31, 2026. It also reflects elimination of estimated intercompany revenues under the pre-existing commercial agreement between IonQ and SkyWater."As we prepare to host our first joint Investor Day today, our updated full-year guidance highlights both the market traction of our quantum platform and the foundational manufacturing scale provided by SkyWater," said Niccolo

Regulatory News: Philip Morris International Inc.’s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, will address investors today at the 2026 Barclays Global Consumer Conference in Boston at 9:45 a.m. ET. The live webcast will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI’s Investor Relations App at www.pmi.com/irapp. 2026 Full-Year Forecast PMI raises its 2026 full-year reported diluted EPS forecast to a range of $7.28 to $7.43 to reflect currency only. Excluding a total 2026 adjustment of $1.07 per share, the forecast range for adjusted diluted EPS of $8.35

New pastille and all-in-one vape formats, expanded oil and softgel offerings, and new flower SKUs build on international growth momentum Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges. "Expanding our product offering in established markets like Australia is central to our internationa

Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Biologics License Application (BLA) meeting with the FDA on track for 4Q 2026 Initiation of BLA submission for detalimogene planned for 4Q 2026 Detalimogene plus surfactant cohort safety run-in successfully cleared; Webinar on surfactant plus detalimogene preclinical data and cohort enrollment guidance planned for October 15, 2026 Well-capitalized with $266 million in cash, cash equivalents, and marketable securities, supporting continued capital discipline and execution toward BLA filing and precommerc

Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical update reported in June 2026 and provide the first broader safety and efficacy assessment of VS-7375 across these tumor types. VS-7375 is a potent

Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity BURLINGTON, Mass. and JERUSALEM, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the publication of results from a pilot study evaluating the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in patients with co-occurring Major Depressive Disorder (MDD) and early-stage Alzheimer’s disease. The results were published in the peer-reviewed Journal of

Closing advances AEVEX’s strategy by combining battle‑proven air, surface, and subsea unmanned systems with scaled U.S. manufacturing, deep customer reach, and CompassX‑enabled autonomy. AEVEX Corp. (NYSE:AVEX), a leading U.S. defense technology company delivering autonomous unmanned systems, AI‑enabled mission software, and advanced ISR and electronic warfare solutions, today announced the closing of its acquisition of BlackSea Technologies ("BlackSea"), one of the largest providers of unmanned surface and subsea vessels in the U.S. defense market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908188362/en/Closing advance

Final 14 MW energized on time, lifting company-wide operating capacity to 206 MW Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:SLNH), a developer of green data centers for intensive computing applications, including AI and Bitcoin mining, today announced two milestones at its Project Kati campus in Willacy County, Texas. The Company has energized the final 14 MW at Project Kati 1, completing the 83 MW site, and has been notified that ERCOT has conditionally classified the full 166 MW Kati campus, including the planned Kati 2 AI expansion, as Base Load in its Batch Zero interconnection process. This press release features multimedia. View the full release here: https://www.bus

CINCINNATI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Investing in castings capacity to support strong demand across commercial engines, aftermarket and defense$11.75 billion transaction, expected to be accretive-a) to adjusted EPS* and free cash flow* in the first yearStrong near and long-term value creation for customers and shareholders GE Aerospace (NYSE:GE) announced today that it has signed an agreement to acquire Consolidated Precision Products (CPP), a leading manufacturer of highly engineered castings, from private investment firms Warburg Pincus and Berkshire Partners.  GE Aerospace Chairman and CEO H. Lawrence Culp, Jr., said, "Investing in mission-critical casting capacity is

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel. The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal Rubin, Chief Financial Officer, will be available for one-on-one

Norwalk, CT, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that it has acquired a Lambda Hyperplane 8-A100 AI compute cluster, powered by eight NVIDIA A100 Tensor Core GPUs, to serve as the dedicated compute backbone for its Swarm Operating System and for the AI and autonomy features being built into Quantum Station, the Company’s battlefield command-and-control platform. The cluster is intended to be installed at Quantum Cyber’s wholly owned manu

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate ("ADC"), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs. CD228V now represents the principal strategic prio

CARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of engagement with the Food and Drug Administration (FDA) to advance the Company’s Phase 3 development program evaluating bezisterim in Parkinson’s disease. "We are working closely with leading experts in Parkinson’s disease clinical development to finalize a Phase 3 trial design that includes MDS-UPDRS1 Part III as the primary endpoint, consistent with the FDA’s longstanding focus on motor symptom improvement in evaluating Parkinson’s therapies,

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September: Cantor Global Healthcare Conference Format: Fireside Chat & 1x1 Investor MeetingsDate: Friday, September 11, 2026Time: 10:55 – 11:25 AM ET Webcast Link: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1 H.C. Wainwright Global Investment ConferenceFormat: Presentation & 1x1 Inve